Last-Resort drug access opens for stubborn colon cancer
NCT ID NCT06195514
First seen Feb 01, 2026 · Last updated May 24, 2026 · Updated 20 times
Summary
This program offers an unapproved drug, fruquintinib, to adults with metastatic colorectal cancer that has worsened after all standard treatments. It is for people who cannot join a clinical trial and have no other options. The goal is to provide access until the drug becomes commercially available or stops helping.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.